
A growing number of cell and gene therapies are advancing toward clinical use, but getting these treatments into the brain remains a challenge. Complex procedures and limited neurosurgical expertise have been cited as major barriers to broader adoption. With that, a new generation of neurotech startups is developing novel approaches to entering the brain.
On November 12, San Francisco-based 4D Surgical announced an $8 million seed round to develop a robotic platform designed to operate inside an MRI scanner, providing real-time imaging during surgery. The company's initial focus is surgeon-assisted stereotactic brain surgery, helping surgeons guide instruments towards precise targets. Longer term, the platform could support the delivery of emerging cell and gene therapies.
The seed round was co-led by Humba Ventures and Inflect, with participation from Also Capital, Julian Capital, Mythos Ventures, and Version One Ventures. Investors see an opportunity in the growing demand for precise brain access, particularly as new cell and gene therapies move through clinical development.
4D Surgical is led by co-founder and CEO Lorne Hofstetter, who previously worked on MRI-guided technology at GE Healthcare. The company's technology grew out of research at the University of Utah, where Hofstetter and colleagues developed a motor capable of operating inside an MRI scanner.
In a 2022 study, Hofstetter and colleagues demonstrated an MRI-compatible motor guiding a biopsy instrument during imaging, including experiments using excised pig tissue. Looking ahead, Hofstetter told Axios that 4D Surgical aims to raise another $30 million in 2027, with potential FDA clearance targeted for late 2028.

The central innovation behind 4D Surgical is its MRI-compatible motor. Conventional robotic motors contain magnetic components that can interfere with MRI scanners, making robotic surgery during imaging difficult. Hofstetter's design uses non-magnetic materials and harnesses the scanner's own magnetic field to generate movement.
MRI-guided neurosurgery is not entirely new. ClearPoint Neuro provides FDA-cleared navigation systems for placing electrodes and catheters in the brain, while AiM Medical Robotics is developing a competing MRI-compatible robotic platform. In May, AiM announced a collaboration with Siemens Healthineers to integrate its technology with MRI scanners.
The technology could also support emerging drug-delivery techniques such as convection-enhanced delivery. This approach uses a catheter inserted directly into brain tissue to infuse therapeutics under pressure, bypassing the blood-brain barrier. MRI can help monitor the distribution of infused agents, while robotic guidance could improve catheter placement.
Other novel entry approaches avoid inserting instruments altogether. Focused ultrasound, for example, temporarily increases blood-brain barrier permeability when combined with circulating microbubbles, allowing systemically administered drugs to enter targeted regions. 4D Surgical's approach allows for broader physical access to brain regions, for procedures including biopsies, electrode implantation, and therapeutic delivery.